About Novaceut Clinical Research
Clinical Trials at Novaceut Clinical Research
During the past decade, Novaceut Clinical Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Novaceut Clinical Research
According to Clinical.Site data, the most researched conditions in "Novaceut Clinical Research" are
"Acute Treatment of Migraine" (1 trials) and "Covid19" (1 trials). Many other conditions were trialed in "Novaceut Clinical Research" in a lesser frequency.
Clinical Trials Intervention Types at Novaceut Clinical Research
Most popular intervention types in "Novaceut Clinical Research" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Bucillamine" (1 trials), "Placebo" (1 trials) and "Rimegepant / BHV3000" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Novaceut Clinical Research
The vast majority of trials in "Novaceut Clinical Research" are
2 trials for "All" genders.
Clinical Trials Status at Novaceut Clinical Research
Currently, there are NaN active trials in "Novaceut Clinical Research".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were undefined completed trials in Novaceut Clinical Research,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Novaceut Clinical Research, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".